Ketamine One makes moves on the research front to advance its work on psychedelics and nutraceuticals

KetamineOne Capital Limited revealed several new milestones in its psychedelic research capabilities.  The company said that its wholly-owned subsidiary KGK Science Inc has applied for a controlled drugs and substances dealer’s licence, which will enable the organization to work with others to conduct clinical trials on psychedelic molecules.  The licence would also allow KGK to act as a centralized distributor for large, multi-location clinical trials, according to a statement.  READ: Ketamine One says its IRP clinic using NeuroCatch Platform to measure brain function in injured veterans Vancouver-based Ketamine One, which has a network of 16 medical clinics across North America, also said that it had completed pre-qualification audits of its Canadian clinics with KGK ahead of future clinical trials. The audits should let KGK conduct clinical trials on psychedelics and nutraceuticals, the company said. Ketamine One told investors it is focusing on the “swift integration” of the medical clinics it recently acquired from Aleafia subsidiary Canabo Medical Corporation. It also said it will work with General Research GmbH to increase its investor awareness in Europe. “Today’s announcements are further evidence of the synergies between our growing clinic network and our contract research offerings,” said Ketamine One’s interim CEO, Adam Deffett in a statement. “KGK will now have the ability to utilize our clinic sites for future trials, gain access to a large patient database and, upon approval, have a narcotic dealer's license. Our goal is that these initiatives will also provide Ketamine One patients with breakthrough treatments through clinical trials and our clinical staff with experience and protocols needed for the eventual expansion of new treatments. “We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One.” Contact Angela at angela@proactiveinvestors.com Follow her on Twitter @AHarmantas